#Clinical Trials

🏢Release 📈 Stocks

Johnson & Johnson Oncology Data Shows 62% Risk Reduction in Prostate Cancer

October 24, 2026 (10 hours ago)

Johnson & Johnson shares gain momentum as new clinical data confirms ERLEADA plus ADT significantly reduces metastasis and mortality risks in prostate…

JNJ

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Orion and Bayer Report 58% Metastasis Risk Reduction in Prostate Cancer Trial

October 24, 2026 (16 hours ago)

Phase III data for darolutamide shows a 58% reduction in metastasis risk for high-risk prostate cancer patients, bolstering the clinical outlook for…

ORNBV BAYN

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Eli Lilly Reports 79% Response Rate for Ovarian Cancer Drug Candidate

October 24, 2026 (16 hours ago)

Eli Lilly's sofetabart mipitecan shows strong clinical efficacy in ovarian cancer trials, achieving a 100% disease control rate in combination therapy.

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Hansa Biopharma Reports 90% Graft Survival Rate in Idefirix Study

October 23, 2026 (1 day ago)

Hansa Biopharma's Idefirix achieves 90% graft failure-free survival at 12 months, with patient survival rates hitting 98%, signaling strong clinical validation for…

HNSA

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Genmab Reports 71% Risk Reduction in Phase 3 Ovarian Cancer Trial

October 23, 2026 (1 day ago)

Genmab's Rina-S hit primary endpoints in a Phase 3 ovarian cancer trial, showing a 71% reduction in disease progression risk and paving…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Jazz Pharmaceuticals Reports 40% Three-Year Survival Rate for Ziihera Combo

October 23, 2026 (1 day ago)

Jazz Pharmaceuticals and partner BeiGene report a 27-month median overall survival for Ziihera-based regimens in HER2+ gastroesophageal cancer, bolstering the case for…

JAZZ BGNE

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Sun Pharma Reports 34% Complete Response Rate in Advanced CSCC Drug Trial

October 23, 2026 (1 day ago)

Sun Pharma shares gain momentum as clinical trial data reveals a 34% complete response rate in locally advanced CSCC patients, with a…

SUNPHARMA

🌍 ASIA Read More →

🏢Release 📈 Stocks

Alebund Pharmaceuticals Unveils Phase IIb Trial Design for AP306 Candidate

October 23, 2026 (1 day ago)

Alebund Pharmaceuticals and partner R1 Therapeutics have detailed the Phase IIb trial design for AP306, marking a key procedural milestone in the…

09637.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks

Innovent Biologics Phase 3 Trial Hits Primary Endpoints for Gastric Cancer

October 23, 2026 (1 day ago)

Innovent Biologics' G-HOPE-001 trial confirms clinical efficacy for its ADC candidate, marking a major milestone for the company's oncology pipeline and potential…

01801.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks — 📊 Neutral

Paradigm Unveils SD-101 Zorblesia for Epidermolysis Bullosa Treatment

October 23, 2026 (1 day ago)

Paradigm introduces Zorblesia (SD-101), a novel topical treatment targeting wounds and lesions in patients suffering from the three major subtypes of Epidermolysis…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Bristol-Myers Squibb Combination Therapy Cuts Disease Progression Risk by 27%

October 23, 2026 (2 days ago)

Bristol-Myers Squibb reports positive clinical trial results as a combination therapy featuring nivolumab reduces disease progression risk by 27% with a median…

BMY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Lakewood-Amedex Shares Rise on Positive Nu-3 Preclinical Data

October 21, 2026 (3 days ago)

Lakewood-Amedex (LABT) advances its clinical pipeline after presenting data showing Nu-3's broad-spectrum efficacy and low resistance potential in treating diabetic foot ulcers.

LABT

🌍 AMERICAS Read More →